Artikel ; Online: Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor.
Vascular health and risk management
2010 Band 6, Seite(n) 419–429
Abstract: Atherothrombosis, thrombus formation as a result of atherosclerotic plaque rupture, is a major modern health problem, often underlying coronary artery disease, stroke, and peripheral arterial disease. After the treatment of an acute thrombotic episode, ... ...
| Abstract | Atherothrombosis, thrombus formation as a result of atherosclerotic plaque rupture, is a major modern health problem, often underlying coronary artery disease, stroke, and peripheral arterial disease. After the treatment of an acute thrombotic episode, long-term therapy is warranted as a secondary prophylaxis of such events and their complications. Because of the importance of platelets' involvement in the initiation and propagation of thrombosis, antiplatelet drugs have come to the forefront of atherothrombotic disease treatment. Dual antiplatelet therapy of aspirin plus clopidogrel--the current standard--has its benefits, but it also has its limitations with regard to its pharmacologic properties and adverse effects. For these reasons, within the last decade or so, the investigation of novel antiplatelet agents has prospered. Here, we review the main pathways through which platelets participate in acute thrombosis and the interruption of these pathways by using novel antiplatelet agents, including P2Y12 receptor antagonists (the recently approved prasugrel, the probable next-in-line ticagrelor, and others). The need for a more individualized patient therapy is evident; although most of the aforementioned pharmaceuticals have the potential to contribute to this, their clinical utility remains to be seen. |
|||||
|---|---|---|---|---|---|---|
| Mesh-Begriff(e) | Adenosine/adverse effects ; Adenosine/analogs & derivatives ; Adenosine/therapeutic use ; Animals ; Blood Platelets/drug effects ; Blood Platelets/metabolism ; Drugs, Investigational/adverse effects ; Drugs, Investigational/therapeutic use ; Humans ; Platelet Aggregation/drug effects ; Platelet Aggregation Inhibitors/adverse effects ; Platelet Aggregation Inhibitors/therapeutic use ; Purinergic P2 Receptor Antagonists ; Receptors, Purinergic P2/blood ; Receptors, Purinergic P2Y12 ; Thrombosis/blood ; Thrombosis/drug therapy ; Thrombosis/etiology ; Ticagrelor ; Treatment Outcome | |||||
| Chemische Substanzen | Drugs, Investigational ; P2RY12 protein, human ; Platelet Aggregation Inhibitors ; Purinergic P2 Receptor Antagonists ; Receptors, Purinergic P2 ; Receptors, Purinergic P2Y12 ; Ticagrelor (GLH0314RVC) ; Adenosine (K72T3FS567) | |||||
| Sprache | Englisch | |||||
| Erscheinungsdatum | 2010-06-01 | |||||
| Erscheinungsland | New Zealand | |||||
| Dokumenttyp | Journal Article ; Review | |||||
| ZDB-ID | 2186568-1 | |||||
| ISSN | 1178-2048 ; 1176-6344 | |||||
| ISSN (online) | 1178-2048 | |||||
| ISSN | 1176-6344 | |||||
| DOI | 10.2147/vhrm.s7054 | |||||
| Signatur |
|
|||||
| Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
| Zs.A 6066: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.